Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
Status:
Completed
Trial end date:
2001-01-01
Target enrollment:
Participant gender:
Summary
The objectives as stated in the study protocol were as follows:
- To investigate the safety and tolerability of three multiple dose regimens of BIA 3-202
(50 mg twice a day, 100 mg twice a day and 200 mg twice a day in healthy young male
volunteers). Part A
- To characterise the steady state pharmacokinetic and pharmacodynamic profile of BIA
3-202 in healthy young males. Part A
- To investigate the safety and tolerability of a single multiple dose regimen (dose to be
determined from Part A) of BIA 3-202, in healthy elderly volunteers. Part B
- To characterise the steady state pharmacokinetic and pharmacodynamic profile of a single
multiple dose regimen (dose to be determined from Part A) of BIA 3- 202 in healthy
elderly volunteers. Part B